Andelyn Biosciences Selected by Hubble Therapeutics to Manufacture Clinical Grade AAV for the Treatment of Leber Congenital Amaurosis

LSTA Stock  USD 2.65  0.04  1.53%   
About 52% of Lisata Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that some traders are interested. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
PRNewswire -- Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization , has...

Read at prnewswire.com
prnewswire News
  

Lisata Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Lisata Therapeutics Fundamental Analysis

We analyze Lisata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Book Value Per Share

Book Value Per Share Comparative Analysis

Lisata Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Lisata Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lisata Therapeutics stock to make a market-neutral strategy. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics with similar companies.

Peers

Lisata Therapeutics Related Equities

LIXTLixte Biotechnology   13.33   
0%
88.0%
PTIXProtagenic Therapeutics   7.69   
0%
51.0%
CADLCandel Therapeutics   7.14   
0%
47.0%
IMNNImunon   3.57   
0%
23.0%
BPTHBio Path   2.99   
0%
19.0%
PULMPulmatrix   2.15   
0%
14.0%
ANTXAN2 Therapeutics   0.75   
0%
4.0%
XOMAOXOMA   0.12   
0%
1.0%
TPSTTempest Therapeutics   1.25   
8.0%
0%
RZLTRezolute   2.18   
14.0%
0%
GLUEMonte Rosa   2.74   
18.0%
0%
MBRXMoleculin Biotech   15.07   
100.0%
0%

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets